GlassScriptPhysician profile
John E Hagele
NPI 1134200629
$1,173.10
in general payments reported to CMS, 2019-2025
15 companies · $23.65 in 2025
The $23.65 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $129 · 2021: $250 · 2022: $126 · 2023: $133 · 2024: $236 · 2025: $23.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.85 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $236.36 | 2019-2021 | |
| Alcon Vision LLC | $195.43 | 2019-2024 | Argos, Clareon |
| Allergan, INC. | $137.36 | 2019-2022 | |
| Rxsight INC | $106.48 | 2021-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $93.83 | 2020-2024 | Idose |
| Amgen INC. | $90.36 | 2024-2025 | Tepezza |
| Abbvie INC. | $68.10 | 2024 | |
| Thea Pharma INC. | $54.77 | 2023-2024 | Iyuzeh |
| Sight Sciences, INC. | $54.68 | 2020-2021 | |
| Biotissue Holdings INC. | $37.22 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $35.66 | 2019-2021 | |
| Dompe US, INC. | $18.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.41 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.36 | 2019 | |
| Iridex Corporation | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hagele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.